Effects of Single Vitamin D₃ Injection (200,000 Units) on Serum Fibroblast Growth Factor 23 and Sclerostin Levels in Subjects with Vitamin D Deficiency.
10.3803/EnM.2017.32.4.451
- Author:
Dongdong ZHANG
1
;
Da Hea SEO
;
Han Seok CHOI
;
Hye Sun PARK
;
Yoon Sok CHUNG
;
Sung Kil LIM
Author Information
1. Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Korea. lsk@yuhs.ac
- Publication Type:Original Article
- Keywords:
Vitamin D3;
Injections, intramuscular;
Fibroblast growth factor 23;
Sclerostin
- MeSH:
Calcium;
Cholecalciferol;
Fibroblast Growth Factors*;
Fibroblasts*;
Homeostasis;
Humans;
Injections, Intramuscular;
Kidney;
Metabolism;
Parathyroid Hormone;
Vitamin D Deficiency*;
Vitamin D*;
Vitamins*
- From:Endocrinology and Metabolism
2017;32(4):451-459
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Vitamin D deficiency remains common in all age groups and affects skeletal and non-skeletal health. Fibroblast growth factor 23 is a bone-derived hormone that regulates phosphate and 1,25-dihydroxyvitamin D homeostasis as a counter regulatory factor. 1,25-Dihydroxyvitamin D stimulates fibroblast growth factor 23 synthesis in bone, while fibroblast growth factor 23 suppresses 1,25-dihydroxyvitamin D production in the kidney. The aim of this study was to evaluate the effects of vitamin D₃ intramuscular injection therapy on serum fibroblast growth factor 23 concentrations, and several other parameters associated with bone metabolism such as sclerostin, dickkopf-1, and parathyroid hormone. METHODS: A total of 34 subjects with vitamin D deficiency (defined by serum 25-hydroxyvitamin D levels below 20 ng/mL) were randomly assigned to either the vitamin D injection group (200,000 units) or placebo treatment group. Serum calcium, phosphate, urine calcium/creatinine, serum 25-hydroxyvitamin D, fibroblast growth factor 23, sclerostin, parathyroid hormone, and dickkopf-1 levels were serially measured after treatment. RESULTS: Comparing the vitamin D injection group with the placebo group, no significant changes were observed in serum fibroblast growth factor 23, parathyroid hormone, or dickkopf-1 levels. Serum sclerostin concentrations transiently increased at week 4 in the vitamin D group. However, these elevated levels declined later and there were no statistically significant differences as compared with baseline levels. CONCLUSION: Serum fibroblast factor 23, sclerostin, parathyroid hormone, and dickkopf-1 levels were not affected significantly by single intramuscular injection of vitamin D₃.
